Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
CHIR-99021
Cat. No.:
OB0225LY-0436
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR and HPLC.
Size:
Product Overview
Description:
CHIR-99021 is a selective GSK-3 inhibitor widely used in stem cell research and other biological studies.
Synonym:
Laduviglusib; CT99021; 252917-06-9; CHIR99021; 6-((2-((4-(2,4-Dichlorophenyl)-5-(4-methyl-1H-imidazol-2-yl)pyrimidin-2-yl)amino)ethyl)amino)nicotinonitrile; GSK-3 Inhibitor XVI; 6-[2-[4-(2,4-Dichlorophenyl)-5-(4-methyl-1H-imidazol-2-yl)pyrimidin-2-ylamino]ethylamino]pyridine-3-carbonitrile
CAS No.:
252917-06-9
Compound CID:
9956119
Formula:
C22H18Cl2N8
Formula Weight:
465.34
Specification
Relative Density:
1.48 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
CHIR-99021 can be used in stem cell differentiation studies or play an important role in regenerative medicine research.
Library Information
Targets:
GSK-3; Wnt/beta-catenin
Receptors:
GSK-3α; GSK-3β; Wnt; β-catenin
Pathways:
Cytoskeletal signaling; Autophagy; PI3K/Akt/mTOR signaling; Stem cells
Plate Number:
AOCL-6
Plate Location:
f3
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
50 mg/mL; 107.45 mM
Solubility:
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 0.93 mg/mL (2 mM)
ALogP:
4.476
HBA_Count:
4
HBD_Count:
3
Rotatable Bond:
7
